197 related articles for article (PubMed ID: 9920790)
21. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
[TBL] [Abstract][Full Text] [Related]
22. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
Ablin J; Cabili S; Lagziel A; Peretz H
Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
[No Abstract] [Full Text] [Related]
23. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.
Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
Drug Metab Dispos; 2004 May; 32(5):484-9. PubMed ID: 15100169
[TBL] [Abstract][Full Text] [Related]
24. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.
Haining RL; Hunter AP; Veronese ME; Trager WF; Rettie AE
Arch Biochem Biophys; 1996 Sep; 333(2):447-58. PubMed ID: 8809086
[TBL] [Abstract][Full Text] [Related]
25. Role of CYP2C9 polymorphism in losartan oxidation.
Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.
Scordo MG; Aklillu E; Yasar U; Dahl ML; Spina E; Ingelman-Sundberg M
Br J Clin Pharmacol; 2001 Oct; 52(4):447-50. PubMed ID: 11678789
[TBL] [Abstract][Full Text] [Related]
27. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
28. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations.
Gaedigk A; Casley WL; Tyndale RF; Sellers EM; Jurima-Romet M; Leeder JS
Can J Physiol Pharmacol; 2001 Oct; 79(10):841-7. PubMed ID: 11697742
[TBL] [Abstract][Full Text] [Related]
29. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy.
Ma J; Yang XY; Qiao L; Liang LQ; Chen MH
J Dig Dis; 2008 May; 9(2):79-83. PubMed ID: 18419640
[TBL] [Abstract][Full Text] [Related]
30. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.
Aynacioglu AS; Brockmöller J; Bauer S; Sachse C; Güzelbey P; Ongen Z; Nacak M; Roots I
Br J Clin Pharmacol; 1999 Sep; 48(3):409-15. PubMed ID: 10510154
[TBL] [Abstract][Full Text] [Related]
31. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
[TBL] [Abstract][Full Text] [Related]
32. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
[TBL] [Abstract][Full Text] [Related]
33. Genetic modulation of oral anticoagulation with warfarin.
Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G
Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.
Leung AY; Chow HC; Kwong YL; Lie AK; Fung AT; Chow WH; Yip AS; Liang R
Blood; 2001 Oct; 98(8):2584-7. PubMed ID: 11588061
[TBL] [Abstract][Full Text] [Related]
35. [Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray].
Li J; Wen SY; Wang R; Chen K; Fang Y; Pei F; Wang SQ
Yao Xue Xue Bao; 2005 Aug; 40(8):695-9. PubMed ID: 16268502
[TBL] [Abstract][Full Text] [Related]
36. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.
García-Martín E; Martínez C; Ladero JM; Gamito FJ; Agúndez JA
Eur J Clin Pharmacol; 2001 Apr; 57(1):47-9. PubMed ID: 11372590
[TBL] [Abstract][Full Text] [Related]
37. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
Lee CR; Goldstein JA; Pieper JA
Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
[TBL] [Abstract][Full Text] [Related]
38. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
39. Genetic analysis of the human cytochrome P450 CYP2C9 locus.
Stubbins MJ; Harries LW; Smith G; Tarbit MH; Wolf CR
Pharmacogenetics; 1996 Oct; 6(5):429-39. PubMed ID: 8946475
[TBL] [Abstract][Full Text] [Related]
40. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]